Therapeutic strategies for spinal muscular atrophy: SMN and beyond

DMM Disease Models and Mechanisms

Volumn 10, Issue 8, 2017, Pages 943-954

  Bowerman, Melissa ^a   Becker, Catherina G ^b   Yáñez Muñoz, Rafael J ^c   Ning, Ke ^d   Wood, Matthew J A ^a   Gillingwater, Thomas H ^b   Talbot, Kevin ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Animal models; Cellular models; Combinatorial therapies; Skeletal muscle; Spinal muscular atrophy; Survival motor neuron

Indexed keywords

AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; SURVIVAL MOTOR NEURON PROTEIN;

ANIMAL MODEL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SPINAL MUSCULAR ATROPHY; SYSTEMIC THERAPY; ANIMAL; DISEASE MODEL; METABOLISM; PATHOLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; MUSCULAR ATROPHY, SPINAL; SMN COMPLEX PROTEINS;

EID: 85027403717     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.030148     Document Type: Review

References (136)

1. Abbott, N. J. (2013). Blood-brain barrier structure and function and the challenges for CNS drug delivery. J. Inherit. Metab. Dis. 36, 437-449.
2. Ackermann, B., Kröber, S., Torres-Benito, L., Borgmann, A., Peters, M., Hosseini Barkooie, S. M., Tejero, R., Jakubik, M., Schreml, J., Milbradt, J. et al. (2013). Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality. Hum. Mol. Genet. 22, 1328-1347.
3. Aghamaleky Sarvestany, A., Hunter, G., Tavendale, A., Lamont, D. J., Llavero Hurtado, M., Graham, L. C., Wishart, T. M. and Gillingwater, T. H. (2014). Label-free quantitative proteomic profiling identifies disruption of ubiquitin homeostasis as a key driver of Schwann cell defects in spinal muscular atrophy. J. Proteome Res. 13, 4546-4557.
4. Armbruster, N., Lattanzi, A., Jeavons, M., Van Wittenberghe, L., Gjata, B., Marais, T., Martin, S., Vignaud, A., Voit, T., Mavilio, F. et al. (2016). Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy. Mol. Ther. Methods Clin. Dev. 3, 16060.
5. Basner-Tschakarjan, E. and Mingozzi, F. (2014). Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Front. Immunol. 5, 350.
6. Bäumer, D., Lee, S., Nicholson, G., Davies, J. L., and Parkinson, N. J., Murray, L. M., Gillingwater, T. H., Ansorge, O., Davies, K. E. and Talbot, K. (2009). Alternative splicing events arealate feature of pathologyinamouse model ofspinal muscular atrophy. PLoS Genet. 5, e1000773.
7. Bergin, A., Kim, G., Price, D.L., Sisodia, S. S., Lee, M. K. and Rabin, B.A. (1997). Identification and characterization of a mouse homologue of the spinal muscular atrophy-determining gene, survival motor neuron. Gene 204, 47-53.
8. Bermúdez Brito, M., Goulielmaki, E. and Papakonstanti, E. A. (2015). Focus on PTEN regulation. Front. Oncol. 5, 166.
9. Bertini, E., Dessaud, E., Mercuri, E., Muntoni, F., Kirschner, J., Reid, C., Lusakowska, A., and Comi, G. P., Cuisset, J.-M., Abitbol, J.-L. et al. (2017). Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 16, 513-522.
10. Betts, C., and Saleh, A. F., Arzumanov, A. A., Hammond, S. M., Godfrey, C., Coursindel, T., Gait, M. J. and Wood, M. J. A. (2012). Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol. Ther. Nucleic Acids 1, e38.
11. Bevan, A. K., and Hutchinson, K. R., Foust, K. D., Braun, L., McGovern, V. L., Schmelzer, L., and Ward, J. G., Petruska, J. C., Lucchesi, P. A., Burghes, A. H. M. et al. (2010). Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum. Mol. Genet. 19, 3895-3905.
12. Bordet, T., Berna, P., Abitbol, J.-L. and Pruss, R. M. (2010). Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound. Pharm. Basel Switz. 3, 345-368.
13. Bowerman, M., Shafey, D. and Kothary, R. (2007). Smn depletion alters profilin II expression and leads to upregulation of the RhoA/ROCK pathway and defects in neuronal integrity. J. Mol. Neurosci. MN 32, 120-131.
14. Bowerman, M., Beauvais, A., Anderson, C. L. and Kothary, R. (2010). Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum. Mol. Genet. 19, 1468-1478.
15. Bowerman, M., and Murray, L. M., Beauvais, A., Pinheiro, B. and Kothary, R. (2012a). A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology. Neuromuscul. Disord. NMD 22, 263-276.
16. Bowerman, M., and Murray, L. M., Boyer, J. G., Anderson, C. L. and Kothary, R. (2012b). Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med. 10, 24.
17. Bowerman, M., and Swoboda, K. J., Michalski, J.-P., Wang, G.-S., Reeks, C., Beauvais, A., Murphy, K., Woulfe, J., Screaton, R.. A., Scott, F. W. et al. (2012c). Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann. Neurol. 72, 256-268.
18. Bowerman, M., Michalski, J.-P., Beauvais, A., and Murray, L. M., DeRepentigny, Y. and Kothary, R. (2014). Defects in pancreatic development and glucose metabolism in SMN-depleted mice independent of canonical spinal muscular atrophy neuromuscular pathology. Hum. Mol. Genet. 23, 3432-3444.
19. Boyd, P. J., Tu, W.-Y., and Shorrock, H. K., Groen, E. J.N., Carter, R. N., Powis, R. A., Thomson, S. R., Thomson, D., Graham, L. C., Motyl, A. A. L. et al. (2017). Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy. PLoS Genet. 13, e1006744.
20. Boyer, J. G., and Murray, L. M., Scott, K., De Repentigny, Y., Renaud, J.-M. and Kothary, R. (2013). Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy. Skelet. Muscle 3, 24.
21. Boza-Morán, M. G., Martínez-Hernández, R., Bernal, S., Wanisch, K., Also-Rallo, E., Le Heron, A., Alías, L., Denis, C., Girard, M., Yee, J.-K. et al. (2015). Decay in survival motor neuron and plastin 3 levels during differentiation of iPSC-derived human motor neurons. Sci. Rep. 5, 11696.
22. Burt, E. C., Towers, P. R. and Sattelle, D. B. (2006). Caenorhabditis elegans in the study of SMN-interacting proteins: a role for SMI-1, an orthologue of human Gemin2 and the identification of novel components of the SMN complex. Invert. Neurosci. 6, 145-159.
23. Caraballo-Miralles, V., Cardona-Rossinyol, A., Garcera, A., Villalonga, P., Soler, R. M., Olmos, G. and Lladó, J. (2012). SMN deficiency attenuates migration of U87MG astroglioma cells through the activation of RhoA. Mol. Cell. Neurosci. 49, 282-289.
24. Carvalho, T., Almeida, F., Calapez, A., Lafarga, M., Berciano, M. T. and Carmo-Fonseca, M. (1999). The spinal muscular atrophy disease gene product, SMN: A link between snRNP biogenesis and the Cajal (coiled) body. J. Cell Biol. 147, 715-728.
25. Chan, Y. B., Miguel-Aliaga, I., Franks, C., Thomas, N., Trulzsch, B., Sattelle, D. B., Davies, K. E. and van den Heuvel, M. (2003). Neuromuscular defects in a Drosophila survival motor neuron gene mutant. Hum. Mol. Genet. 12, 1367-1376.
26. Chang, H.C.-H., Dimlich, D. N., Yokokura, T., Mukherjee, A., Kankel, M.W., Sen, A., Sridhar, V., Fulga, T. A., Hart, A. C., Van Vactor, D. et al. (2008). Modeling spinal muscular atrophy in Drosophila. PLoS ONE 3, e3209.
27. Charroux, B., Pellizzoni, L., Perkinson, R. A., Yong, J., Shevchenko, A., Mann, M. and Dreyfuss, G. (2000). Gemin4. A novel component of the SMN complex that is found in both gems and nucleoli. J. Cell Biol. 148, 1177-1186.
28. Crawford, T. O. and Pardo, C. A. (1996). The neurobiology of childhood spinal muscular atrophy. Neurobiol. Dis. 3, 97-110.
29. De Filippis, L., Zalfa, C. and Ferrari, D. (2017). Neural Stem Cells and Human induced pluripotent stem cells to model rare CNS diseases. CNS Neurol. Disord. Drug Targets doi:10.2174/1871527316666170615121753 [Epub ahead of print].
30. Deguise, M.-O., De Repentigny, Y., McFall, E., Auclair, N., Sad, S. and Kothary, R. (2017). Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice. Hum. Mol. Genet 26, 801-819.
31. De Vos, J., Bouckenheimer, J., Sansac, C., Lemaître, J.-M. and Assou, S. (2016). Human induced pluripotent stem cells: a disruptive innovation. Curr. Res. Transl. Med. 64, 91-96.
32. Doktor, T. K., Hua, Y., Andersen, H. S., Brøner, S., and Liu, Y. H., Wieckowska, A., Dembic, M., Bruun, G. H., Krainer, A. R. and Andresen, B. S. (2017). RNA-sequencing of a mouse-model of spinal muscular atrophy reveals tissue-wide changes in splicing of U12-dependent introns. Nucleic Acids Res. 45, 395-416.
33. Donlin-Asp, P. G., Bassell, G. J. and Rossoll, W. (2016). A role for the survival of motor neuron protein in mRNP assembly and transport. Curr. Opin. Neurobiol. 39, 53-61.
34. Douglas, A. G. L. and Wood, M. J. A. (2013). Splicing therapy for neuromuscular disease. Mol. Cell. Neurosci. 56, 169-185.
35. Duque, S. I., and Arnold, W. D., Odermatt, P., Li, X., Porensky, P. N., Schmelzer, L., Meyer, K., Kolb, S. J., Schumperli, D., Kaspar, B. K. et al. (2015). A large animal model of Spinal Muscular Atrophy and correction of phenotype. Ann. Neurol. 77, 399-414.
36. d'Ydewalle, C. and Sumner, C. J. (2015). Spinal muscular atrophy therapeutics: where do we stand? Neurother. J. Am. Soc. Exp. Neurother. 12, 303-316.
37. Ebert, A. D., Yu, J., Rose, F. F., and Mattis, V. B., Lorson, C. L., Thomson, J. A. and Svendsen, C. N. (2009). Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277-280.
38. Ebert, A. D., Liang, P. and Wu, J. C. (2012). Induced pluripotent stem cells as a disease modeling and drug screening platform. J. Cardiovasc. Pharmacol. 60, 408-416.
39. Fallini, C., Bassell, G. J. and Rossoll, W. (2010). High-efficiency transfection of cultured primary motor neurons to study protein localization, trafficking, and function. Mol. Neurodegener. 5, 17.
40. Fan, L. and Simard, L. R. (2002). Survival motor neuron (SMN) protein: role in neurite outgrowth and neuromuscular maturation during neuronal differentiation and development. Hum. Mol. Genet. 11, 1605-1614.
41. Finkel, R. S., and Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Yamashita, M., Rigo, F., Hung, G., Schneider, E. et al. (2016). Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet Lond. Engl. 388, 3017-3026.
42. Foust, K. D., Wang, X., McGovern, V. L., Braun, L., and Bevan, A. K., Haidet, A. M., Le, T. T., and Morales, P. R., Rich, M. M., Burghes, A. H. M. et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28, 271-274.
43. Gabanella, F., Butchbach, M. E. R., Saieva, L., Carissimi, C., Burghes, A. H. M. and Pellizzoni, L. (2007). Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS ONE 2, e921.
44. Gennarelli, M., Lucarelli, M., Capon, F., Pizzuti, A., Merlini, L., Angelini, C., Novelli, G. and Dallapiccola, B. (1995). Survival motor-neuron gene transcript analysis in muscles from spinal muscular-atrophy patients. Biochem. Biophys. Res. Commun. 213, 342-348.
45. Gillingwater, T. H. (2016). Dawn of a new therapeutic era for spinal muscular atrophy. Lancet Lond. Engl. 388, 2964-2965.
46. Gresslien, T. and Agewall, S. (2016). Troponin and exercise. Int. J. Cardiol. 221, 609-621.
47. Groen, E. J. N. and Gillingwater, T. H. (2015). UBA1: at the crossroads of ubiquitin homeostasis and neurodegeneration. Trends Mol. Med. 21, 622-632.
48. Hamilton, G. and Gillingwater, T. H. (2013). Spinal muscular atrophy: going beyond the motor neuron. Trends Mol. Med. 19, 40-50.
49. Hammond, S. M., and Gogliotti, R. G., Rao, V., Beauvais, A., Kothary, R. and DiDonato, C. J. (2010). Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late. PLoS ONE 5, e15887.
50. Hammond, S. M., Hazell, G., Shabanpoor, F., Saleh, A. F., Bowerman, M., and Sleigh, J. N., Meijboom, K. E., Zhou, H., Muntoni, F., Talbot, K. et al. (2016). Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 113, 10962-10967.
51. Hao, L. T., Burghes, A. H. M. and Beattie, C. E. (2011). Generation and Characterization of a genetic zebrafish model of SMA carrying the human SMN2 gene. Mol. Neurodegener. 6, 24.
52. Hao, L. T., Wolman, M., Granato, M. and Beattie, C. E. (2012). Survival motor neuron affects plastin 3 protein levels leading to motor defects. J. Neurosci. Off. J. Soc. Neurosci. 32, 5074-5084.
53. Hao, L. T., and Duy, P. Q., Jontes, J. D., Wolman, M., Granato, M. and Beattie, C. E. (2013). Temporal requirement for SMN in motoneuron development. Hum. Mol. Genet. 22, 2612-2625.
54. Hao, L. T., and Duy, P. Q., Jontes, J. D. and Beattie, C. E. (2015). Motoneuron development influences dorsal root ganglia survival and Schwann cell development in a vertebrate model of spinal muscular atrophy. Hum. Mol. Genet. 24, 346-360.
55. Heesen, L., Peitz, M., Torres-Benito, L., Hölker, I., Hupperich, K., Dobrindt, K., Jungverdorben, J., Ritzenhofen, S., Weykopf, B., Eckert, D. et al. (2016). Plastin 3 is upregulated in iPSC-derived motoneurons from asymptomatic SMN1-deleted individuals. Cell. Mol. Life Sci. CMLS 73, 2089-2104.
56. Heier, C. R., Satta, R., Lutz, C. and DiDonato, C. J. (2010). Arrhythmia and cardiac defects are afeature ofspinal muscular atrophy model mice. Hum. Mol. Genet. 19, 3906-3918.
57. Hensel, N. and Claus, P. (2017). The actin cytoskeletoninSMA and ALS: how does it contribute to motoneuron degeneration? Neurosci. Rev. J. Bringing Neurobiol. Neurol. Psychiatry. doi:10.1177/1073858417705059 [Epub ahead of print].
58. Hensel, N., Stockbrugger, I., Rademacher, S., Broughton, N., Brinkmann, H., Grothe, C. and Claus, P. (2014). Bilateral crosstalk of rho- and extracellular-signal-regulated-kinase (ERK) pathways is confined to an unidirectional mode in spinal muscular atrophy (SMA). Cell. Signal. 26, 540-548.
59. Hosseinibarkooie, S., Peters, M., Torres-Benito, L., Rastetter, R. H., Hupperich, K., Hoffmann, A., Mendoza-Ferreira, N., Kaczmarek, A., Janzen, E., Milbradt, J. et al. (2016). The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. Am. J. Hum. Genet. 99, 647-665.
60. Hsieh-Li, H.M., Chang, J.-G., Jong, Y.-J., Wu, M.-H., Wang, N.-M., Tsai, C.H. and Li, H. (2000). A mouse model for spinal muscular atrophy. Nat. Genet. 24, 66-70.
61. Hunter, G., Aghamaleky Sarvestany, A., Roche, S. L., Symes, R. C. and Gillingwater, T. H. (2014). SMN-dependent intrinsic defects in Schwann cells in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 23, 2235-2250.
62. Hunter, G., and Powis, R. A., Jones, R. A., Groen, E. J. N., Shorrock, H. K., and Lane, F. M., Zheng, Y., Sherman, D. L., Brophy, P. J. and Gillingwater, T. H. (2016). Restoration of SMN in Schwann cells reverses myelination defects and improves neuromuscular function in spinal muscular atrophy. Hum. Mol. Genet. 25, 2853-2861.
63. Hwee, D. T., Kennedy, A., Ryans, J., Russell, A. J., Jia, Z., and Hinken, A. C., Morgans, D. J., Malik, F. I. and Jasper, J. R. (2014). Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS ONE 9, e96921.
64. Hwee, D. T., and Kennedy, A. R., Hartman, J. J., Ryans, J., Durham, N., Malik, F. I. and Jasper, J. R. (2015). The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in arat model of heart failure. J. Pharmacol. Exp. Ther. 353, 159-168.
65. Kaifer, K. A., Villalón, E., and Osman, E. Y., Glascock, J. J., Arnold, L. L., Cornelison, D. D. W. and Lorson, C. L. (2017). Plastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy. JCI Insight 2, e89970.
66. Kariya, S., Park, G.-H., Maeno-Hikichi, Y., Leykekhman, O., Lutz, C., Arkovitz, M. S., Landmesser, L. T. and Monani, U. R. (2008). Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17, 2552-2569.
67. Kaufmann, P., and McDermott, M. P., Darras, B. T., Finkel, R. S., and Sproule, D. M., Kang, P. B., Oskoui, M., Constantinescu, A., and Gooch, C. L., Foley, A. R. et al. (2012). Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 79, 1889-1897.
68. Kong, L., Wang, X., Choe, D. W., Polley, M., and Burnett, B. G., Bosch-Marcé, M., Griffin, J. W., Rich, M. M. and Sumner, C. J. (2009). Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J. Neurosci. Off. J. Soc. Neurosci. 29, 842-851.
69. Lachyankar, M. B., Sultana, N., Schonhoff, C. M., Mitra, P., Poluha, W., Lambert, S., Quesenberry, P. J., and Litofsky, N. S., Recht, L. D., Nabi, R. et al. (2000). A role for nuclear PTEN in neuronal differentiation. J. Neurosci. Off. J. Soc. Neurosci. 20, 1404-1413.
70. Le, T. T., and Pham, L. T., Butchbach, M. E. R., Zhang, H. L., and Monani, U. R., Coovert, D. D., Gavrilina, T. O., Xing, L., Bassell, G. J. and Burghes, A. H. M. (2005). SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14, 845-857.
71. Lee, S.-J. and McPherron, A. C. (2001). Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. USA 98, 9306-9311.
72. Lee, E.-J., De Winter, J. M., Buck, D., Jasper, J. R., Malik, F. I., Labeit, S., Ottenheijm, C. A. and Granzier, H. (2013). Fast skeletal muscle troponin activation increases force of mouse fast skeletal muscle and ameliorates weakness due to nebulin-deficiency. PLoS ONE 8, e55861.
73. Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P. and Zeviani, M. (1995). Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155-165.
74. Li, L., Liu, F. and Ross, A. H. (2003). PTEN regulation of neural development and CNS stem cells. J. Cell. Biochem. 88, 24-28.
75. Li, D. K., Tisdale, S., Lotti, F. and Pellizzoni, L. (2014). SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease. Semin. Cell Dev. Biol. 32, 22-29.
76. Ling, K. K. Y., and Gibbs, R. M., Feng, Z. and Ko, C.-P. (2012). Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 21, 185-195.
77. Lippmann, E. S., Al-Ahmad, A., Azarin, S. M., Palecek, S. P. and Shusta, E. V. (2014). A retinoic acid-enhanced, multicellular human blood-brain barrier model derived from stem cell sources. Sci. Rep. 4, 4160.
78. Little, D., and Valori, C. F., Mutsaers, C. A., Bennett, E. J., Wyles, M., Sharrack, B., Shaw, P.J., Gillingwater, T. H., Azzouz, M. and Ning, K.(2015). PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy. Mol. Ther. J. Am. Soc. Gene Ther. 23, 270-277.
79. Liu, Q. and Dreyfuss, G. (1996). A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 15, 3555-3565.
80. Liu, M., and Hammers, D. W., Barton, E. R. and Sweeney, H. L. (2016). Activin receptor type IIB inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy. PLoS ONE 11, e0166803.
81. Lorson, C. L., Hahnen, E., Androphy, E. J. and Wirth, B. (1999). A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 96, 6307-6311.
82. Lotti, F., and Imlach, W. L., Saieva, L., Beck, E. S., and Hao, L. T., Li, D. K., Jiao, W., Mentis, G. Z., and Beattie, C. E., McCabe, B. D. et al. (2012). An SMN-dependent U12 splicing event essential for motor circuit function. Cell 151, 440-454.
83. Luo, L., Jan, L. Y. and Jan, Y.-N. (1997). Rho family small GTP-binding proteins in growth cone signalling. Curr. Opin. Neurobiol. 7, 81-86.
84. Mariot, V., Joubert, R., Hourde, C., Servais, L., and Hanna, M. G., Maisonobe, T., Muntoni, F., Feasson, L., and Panse, R. L., Benvensite, O. et al. (2017). Myostatin inhibition for neuromuscular disorders: defining the good candidate. Neuromuscul. Disord. 27, S8.
85. Martínez-Hernández, R., Soler-Botija, C., Also, E., Alias, L., Caselles, L., Gich, I., Bernal, S. and Tizzano, E. F. (2009). The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. J. Neuropathol. Exp. Neurol. 68, 474-481.
86. McGovern, V. L., Massoni-Laporte, A., Wang, X., and Le, T. T., Le, H. T., Beattie, C. E., Rich, M. M. and Burghes, A. H. M. (2015). Plastin 3 expression does not modify spinal muscular atrophy severity in the Δ7 SMA mouse. PLoS ONE 10, e0132364.
87. McPherron, A. C., Lawler, A. M. and Lee, S.-J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83-90.
88. McWhorter, M. L., and Monani, U. R., Burghes, A. H. M. and Beattie, C. E. (2003). Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J. Cell Biol. 162, 919-931.
89. Miguel-Aliaga, I., Culetto, E., and Walker, D. S., Baylis, H. A., Sattelle, D. B. and Davies, K. E. (1999). The Caenorhabditis elegans orthologue of the human gene responsible for spinal muscular atrophy is a maternal product critical for germline maturation and embryonic viability. Hum. Mol. Genet. 8, 2133-2143.
90. Miguel-Aliaga, I., Chan, Y. B., Davies, K. E. and van den Heuvel, M. (2000). Disruption of SMN function by ectopic expression of the human SMN gene in Drosophila. FEBS Lett. 486, 99-102.
91. Miller, N., Feng, Z., Edens, B. M., Yang, B., Shi, H., Sze, C. C., and Hong, B. T., Su, S. C., Cantu, J. A., Topczewski, J. et al. (2015). Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy. J. Neurosci. Off. J. Soc. Neurosci. 35, 6038-6050.
92. Mitchell, D. J., and Kim, D. T., Steinman, L., Fathman, C. G. and Rothbard, J. B. (2000). Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. Off. J. Am. Pept. Soc. 56, 318-325.
93. Monani, U. R., Sendtner, M., Coovert, D. D., and Parsons, D. W., Andreassi, C., Le, T. T., Jablonka, S., Schrank, B., Rossoll, W., Rossol, W. et al. (2000). The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9, 333-339.
94. Munsat, T. L. and Davies, K. E. (1992). International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscul. Disord. NMD 2, 423-428.
95. Murray, L. M., and Comley, L. H., Thomson, D., Parkinson, N., Talbot, K. and Gillingwater, T. H. (2008). Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17, 949-962.
96. Mutsaers, C. A., and Wishart, T. M., Lamont, D. J., Riessland, M., Schreml, J., and Comley, L. H., Murray, L. M., Parson, S. H., Lochmüller, H., Wirth, B. et al. (2011). Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. Hum. Mol. Genet. 20, 4334-4344.
97. Nölle, A., Zeug, A., van Bergeijk, J., Tönges, L., Gerhard, R., Brinkmann, H., Al Rayes, S., Hensel, N., Schill, Y., Apkhazava, D. et al. (2011). The spinal muscular atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin. Hum. Mol. Genet. 20, 4865-4878.
98. Oprea, G.E., Kröber, S., and McWhorter, M. L., Rossoll, W., Müller, S., Krawczak, M., and Bassell, G. J., Beattie, C. E. and Wirth, B. (2008). Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320, 524-527.
99. Pardridge, W. M. (2005). The blood-brain barrier: bottleneck in brain drug development. NeuroRx J. Am. Soc. Exp. Neurother. 2, 3-14.
100. Passini, M. A., Bu, J., Roskelley, E. M., and Richards, A. M., Sardi, S. P., O'Riordan, C. R., Klinger, K. W., Shihabuddin, L. S. and Cheng, S. H. (2010). CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J. Clin. Invest. 120, 1253-1264.
101. Paushkin, S., Charroux, B., Abel, L., Perkinson, R. A., Pellizzoni, L. and Dreyfuss, G. (2000). The survival motor neuron protein of Schizosacharomyces pombe. Conservation of survival motor neuron interaction domains in divergent organisms. J. Biol. Chem. 275, 23841-23846.
102. Pearn, J. (1980). Classification of spinal muscular atrophies. Lancet Lond. Engl. 1, 919-922.
103. Pinard, E., Green, L., Reutlinger, M., Weetall, M., and Naryshkin, N. A., Baird, J., Chen, K. S., and Paushkin, S. V., Metzger, F. and Ratni, H. (2017). Discovery of a novel class of survival motor neuron 2 splicing modifiers for the treatment of spinal muscular atrophy. J. Med. Chem. 60, 4444-4457.
104. Powis, R. A. and Gillingwater, T. H. (2016). Selective loss of alpha motor neurons with sparing of gamma motor neurons and spinal cord cholinergic neurons in a mouse model of spinal muscular atrophy. J. Anat. 228, 443-451.
105. Powis, R. A., Karyka, E., Boyd, P., Côme, J., and Jones, R. A., Zheng, Y., Szunyogova, E., Groen, E. J. N., Hunter, G., Thomson, D. et al. (2016). Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy. JCI Insight 1, e87908.
106. Praveen, K., Wen, Y. and Matera, A. G. (2012). A Drosophila model of spinal muscular atrophy uncouples snRNP biogenesis functions of survival motor neuron from locomotion and viability defects. Cell Rep. 1, 624-631.
107. Praveen, K., Wen, Y., Gray, K. M., and Noto, J. J., Patlolla, A. R., Van Duyne, G. D. and Matera, A. G. (2014). SMA-causing missense mutations in survival motor neuron (Smn) display a wide range of phenotypes when modeled in drosophila. PLoS Genet. 10, e1004489.
108. Ratni, H., and Karp, G. M., Weetall, M., Naryshkin, N. A., and Paushkin, S. V., Chen, K. S., McCarthy, K. D., Qi, H., Turpoff, A., Woll, M. G. et al. (2016). Specific correction of alternative survival motor neuron 2 splicing by small molecules: discovery of a potential novel medicine to treat spinal muscular atrophy. J. Med. Chem. 59, 6086-6100.
109. Rindt, H., and Buckley, D. M., Vale, S. M., Krogman, M., Rose, F. F., Garcia, M. L. and Lorson, C. L. (2012). Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy. Neuromuscul. Disord. NMD 22, 277-285.
110. Rochette, C. F., Gilbert, N. and Simard, L. R. (2001). SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens. Hum. Genet. 108, 255-266.
111. Rodino-Klapac, L. R., Haidet, A. M., Kota, J., Handy, C., Kaspar, B. K. and Mendell, J. R. (2009). Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 39, 283-296.
112. Rouhani, F., Kumasaka, N., de Brito, M. C., Bradley, A., Vallier, L. and Gaffney, D. (2014). Genetic background drives transcriptional variation in human induced pluripotent stem cells. PLoS Genet. 10, e1004432.
113. Rudnik-Schöneborn, S., Hausmanowa-Petrusewicz, I., Borkowska, J. and Zerres, K. (2001). The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur. Neurol. 45, 174-181.
114. Russell, A. J., and Hartman, J. J., Hinken, A. C., Muci, A. R., Kawas, R., Driscoll, L., Godinez, G., Lee, K. H., Marquez, D., Browne, W. F. et al. (2012). Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat. Med. 18, 452-455.
115. Sano, T., Lin, H., Chen, X., Langford, L. A., Koul, D., and Bondy, M. L., Hess, K. R., Myers, J. N., and Hong, Y. K., Yung, W. K. et al. (1999). Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 59, 1820-1824.
116. Schrank, B., Götz, R., Gunnersen, J.M., and Ure, J. M., Toyka, K. V., Smith, A. G. and Sendtner, M. (1997). Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl. Acad. Sci. USA 94, 9920-9925.
117. Shababi, M., Habibi, J., Yang, H. T., and Vale, S. M., Sewell, W. A. and Lorson, C. L. (2010). Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum. Mol. Genet. 19, 4059-4071.
118. Singh, N. K., and Singh, N. N., Androphy, E. J. and Singh, R. N. (2006). Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol. 26, 1333-1346. doi:10.1038/gt.2017.34 [Epub ahead of print].
119. Singh, N. N., and Howell, M. D., Androphy, E. J. and Singh, R. N. (2017). How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther. doi:10.1038/gt.2017.34 [Epub ahead of print].
120. Sleigh, J. N., Barreiro-Iglesias, A., Oliver, P. L., Biba, A., Becker, T., Davies, K. E., Becker, C. G. and Talbot, K. (2014). Chondrolectin affects cell survival and neuronal outgrowth in in vitro and in vivo models of spinal muscular atrophy. Hum. Mol. Genet. 23, 855-869.
121. Somers, E., Stencel, Z., Wishart, T. M., Gillingwater, T. H. and Parson, S. H. (2012). Density, calibre and ramification of muscle capillaries are altered in a mouse model of severe spinal muscular atrophy. Neuromuscul. Disord. NMD 22, 435-442.
122. Somers, E., and Lees, R. D., Hoban, K., Sleigh, J. N., Zhou, H., Muntoni, F., Talbot, K., Gillingwater, T.H. and Parson, S.H. (2016). Vasculardefects and spinal cord hypoxia in spinal muscular atrophy. Ann. Neurol. 79, 217-230.
123. Stevens, L., Bastide, B., Maurage, C. A., Dupont, E., Montel, V., Cieniewski-Bernard, C., Cuisset, J. M., Vallee, L. and Mounier, Y. (2008). Childhood spinal muscular atrophy induces alterations in contractile and regulatory protein isoform expressions. Neuropathol. Appl. Neurobiol. 34, 659-670.
124. Stratigopoulos, G., Lanzano, P., Deng, L., Guo, J., Kaufmann, P., Darras, B., Finkel, R., Tawil, R., McDermott, M. P., Martens, W. et al. (2010). Association of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females. Arch. Neurol. 67, 1252-1256.
125. Sumner, C. J., and Wee, C. D., Warsing, L. C., Choe, D. W., and Ng, A. S., Lutz, C. and Wagner, K. R. (2009). Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Hum. Mol. Genet. 18, 3145-3152.
126. Szunyogova, E., Zhou, H., Maxwell, G. K., and Powis, R. A., Francesco, M., Gillingwater, T. H. and Parson, S. H. (2016). Survival motor neuron (SMN) protein is required for normal mouse liver development. Sci. Rep. 6, 34635.
127. Tamura, M., Gu, J., Danen, E. H. J., Takino, T., Miyamoto, S. and Yamada, K. M. (1999). PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem. 274, 20693-20703.
128. Thomson, A. K., Somers, E., Powis, R. A., and Shorrock, H. K., Murphy, K., Swoboda, K. J., Gillingwater, T. H. and Parson, S. H. (2017). Survival of motor neurone protein is required for normal postnatal development of the spleen. J. Anat. 230, 337-346.
129. Towne, C., and Schneider, B. L., Kieran, D., Redmond, D. E. and Aebischer, P. (2010). Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther. 17, 141-146.
130. Valori, C. F., Ning, K., Wyles, M., Mead, R. J., and Grierson, A. J., Shaw, P. J. and Azzouz, M. (2010). Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med. 2, 35ra42.
131. Walker, M. P., and Rajendra, T. K., Saieva, L., Fuentes, J. L., Pellizzoni, L. and Matera, A. G. (2008). SMN complex localizes to the sarcomeric Z-disc and is a proteolytic target of calpain. Hum. Mol. Genet. 17, 3399-3410.
132. Wehner, K. A., Ayala, L., Kim, Y., Young, P. J., and Hosler, B. A., Lorson, C. L., Baserga, S. J. and Francis, J. W. (2002). Survival motor neuron protein in the nucleolus of mammalian neurons. Brain Res. 945, 160-173.
133. Will, C. L. and Luhrmann, R. (2001). Spliceosomal UsnRNP biogenesis, structure and function. Curr. Opin. Cell Biol. 13, 290-301.
134. Wishart, T. M., and Mutsaers, C. A., Riessland, M., Reimer, M. M., Hunter, G., Hannam, M.L., and Eaton, S. L., Fuller, H. R., Roche, S.L., Somers, E. et al. (2014). Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy. J. Clin. Invest. 124, 1821-1834.
135. Yanyan, C., Yujin, Q., Jinli, B., Yuwei, J., Hong, W. and Fang, S. (2014). Correlation of PLS3 expression with disease severity in children with spinal muscular atrophy. J. Hum. Genet. 59, 24-27.
136. Zhou, H., Meng, J., Marrosu, E., Janghra, N., Morgan, J. and Muntoni, F. (2015). Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response. Hum. Mol. Genet. 24, 6265-6277.